PRIVATE BETWEEN THE PARTIES PharmAthene, Inc. Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Confidential Portions denoted by [***]Manufacturing and Marketing Licence Agreement • August 19th, 2008 • Pharmathene, Inc • Pharmaceutical preparations
We hereby agree that the exclusive period under clause 2.2 of each of the above licenses is extended and the exclusive period is for the period that the license remains in effect and is for the benefit of you or your assignees. In each case, such exclusive period shall (without prejudice to our rights to terminate the licences in accordance with their terms) be subject to termination only if you or any party to whom you assign your license agreements does not diligently pursue development of products using the respective technology licensed to you by us, by prior written notice to Avecia (or an Avecia assignee) of an intent to terminate the exclusive period. Such proposed termination is subject to the dispute resolution procedure of Clause 14.1 of the [***] License and Clause 16.1 of the [***] License. This extension is subject to
